General Announcement::NOTIFICATION OF CHARGE AGAINST GENERAL PRACTITIONER

MEDINEX LIMITED

Incorporated in the Republic of Singapore

Registration No. 200900689W

NOTIFICATION OF CHARGE AGAINST GENERAL PRACTITIONER

The Board of Directors (the "Board") of Medinex Limited (the "Company" and together with its subsidiaries, the "Group") wishes to announce that the Company has been informed by Dr. Jitendra Kumar Sen ("Dr. Sen"), the director of the Company's subsidiary, Sen Med Holdings Pte. Ltd. ("Sen Med") and a general practitioner of the Group, that he was charged on 19 August 2021 by the Health Sciences Authority ("HSA") for supplying by retail sale of codeine cough preparation to the same individual more than once within a period of four (4) days which is a restriction under Regulation 14(1)(b) of the Health Products (Therapeutic Products) Regulations 2016. Under the charge, he has contravened Section 17(1) of the Health Products Act, Chapter 122D, and committed an offence punishable under Section 17(3) of the same Act, Chapter.

The Company has spoken to Dr. Sen to understand the circumstances surrounding the charge as well as stressed upon Dr. Sen of his obligations to comply with relevant laws and regulations relating to his medical practice.

As the Company understands that the matter is currently ongoing, it will release further announcements to update the Company's shareholders of any material developments in connection with the foregoing matter.

Dr. Sen is currently able to continue with the operation of the clinics under Sen Med. If necessary, and for the avoidance of doubt, the Company has the ability to source for replacement qualified general practitioners and the approval from the Ministry of Health for the change in clinic manager can typically be obtained within one (1) business day. Accordingly, the Company does not expect the charge on Dr. Sen to have any material financial impact on the Group nor affect the business operations of the Group.

By Order of the Board

Jessie Low Mui Choo

Executive Director and Chief Executive Officer

20 August 2021

This announcement has been prepared by the Company and reviewed by the Company's Sponsor, Novus Corporate Finance Pte. Ltd. (the "Sponsor"), in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #18-03B Suntec Tower 1, Singapore 038987, telephone [phone].

1